1. Forced degradation and impurity profiling: recent trends in analytical perspectives;Jain;J. Pharm. Biomed. Anal.,2013
2. ICH Harmonized Guideline: Impurities in New Drug Substances Q3A (R2), ICH Steering Committee, Geneva, Switzerland, 2006.
3. ICH Harmonized Guideline: Impurities in New Drug Products Q3B (R2), ICH Steering Committee, Geneva, Switzerland, 2006.
4. The United States Pharmacopeia, USP36-NF31, Impurities in Drug Substances and Drug Products, U.S. Pharmacopeial Convention Inc., Rockville, MD, USA, 2013 (Chapter 1086).
5. Evaluating impurities in drugs (Part I of III);Wadekar;Pharm. Technol.,2012